Home Cart Sign in  
Chemical Structure| 1400-61-9 Chemical Structure| 1400-61-9

Structure of Nystatin
CAS No.: 1400-61-9

Chemical Structure| 1400-61-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Nystatin is a polyene antifungal drug used to treat fungal infections of the mouth, skin, vagina, and intestinal tract.

Synonyms: Fungicidin

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Nystatin

CAS No. :1400-61-9
Formula : C47H75NO17
M.W : 926.09
SMILES Code : C[C@@H]1OC(C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@@](O)(O[C@H]2C[C@H](/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@@H]([C@@H](O)[C@H]1C)C)O[C@H]3[C@@H](O)[C@@H](N)[C@H](O)[C@@H](C)O3)C[C@H](O)[C@H]2C(O)=O)=O
Synonyms :
Fungicidin
MDL No. :MFCD00036240

Safety of Nystatin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
C. lipolytica 0.125–16 µg/ml 24 and 48 hours To evaluate the in vitro activity of nystatin and liposomal nystatin against C. lipolytica, results showed that nystatin and liposomal nystatin exhibited good activity against all tested Candida species. J Clin Microbiol. 2002 Apr;40(4):1406-12.
C. lusitaniae 0.125–16 µg/ml 24 and 48 hours To evaluate the in vitro activity of nystatin and liposomal nystatin against C. lusitaniae, results showed that nystatin and liposomal nystatin exhibited good activity against all tested Candida species. J Clin Microbiol. 2002 Apr;40(4):1406-12.
C. krusei 0.125–16 µg/ml 24 and 48 hours To evaluate the in vitro activity of nystatin and liposomal nystatin against C. krusei, results showed that nystatin and liposomal nystatin exhibited good activity against all tested Candida species. J Clin Microbiol. 2002 Apr;40(4):1406-12.
C. parapsilosis 0.125–16 µg/ml 24 and 48 hours To evaluate the in vitro activity of nystatin and liposomal nystatin against C. parapsilosis, results showed that nystatin and liposomal nystatin exhibited good activity against all tested Candida species. J Clin Microbiol. 2002 Apr;40(4):1406-12.
C. tropicalis 0.125–16 µg/ml 24 and 48 hours To evaluate the in vitro activity of nystatin and liposomal nystatin against C. tropicalis, results showed that nystatin and liposomal nystatin exhibited good activity against all tested Candida species. J Clin Microbiol. 2002 Apr;40(4):1406-12.
C. glabrata 0.125–16 µg/ml 24 and 48 hours To evaluate the in vitro activity of nystatin and liposomal nystatin against C. glabrata, results showed that nystatin and liposomal nystatin exhibited good activity against all tested Candida species. J Clin Microbiol. 2002 Apr;40(4):1406-12.
C. albicans 0.125–16 µg/ml 24 and 48 hours To evaluate the in vitro activity of nystatin and liposomal nystatin against C. albicans, results showed that nystatin and liposomal nystatin exhibited good activity against all tested Candida species. J Clin Microbiol. 2002 Apr;40(4):1406-12.
HEK-293 cells 3.9 to 125 µg/mL 24 hours To evaluate the cytotoxicity of Nystatin nanocomposites on HEK-293 cells. Results showed that nanocomposites inhibited only 12% growth of HEK-293 cells at 125 µg/mL, indicating low cytotoxicity. Molecules. 2023 Feb 15;28(4):1836.
Candida dubliniensis CD36 3.52 mg/L (MIC) 24 hours Evaluation of the minimum inhibitory concentration (MIC) of Nystatin against Candida dubliniensis CD36, showing an MIC of 3.52 mg/L. essential oil inhibits virulence patterns of Candida spp. and potentiates the effects of fluconazole and nystatin in vitro.
Candida krusei ATCC 6258 1.40 mg/L (MIC) 24 hours Evaluation of the minimum inhibitory concentration (MIC) of Nystatin against Candida krusei ATCC 6258, showing an MIC of 1.40 mg/L. essential oil inhibits virulence patterns of Candida spp. and potentiates the effects of fluconazole and nystatin in vitro.
Candida albicans ATCC 10231 0.48 mg/L (MIC) 24 hours Evaluation of the minimum inhibitory concentration (MIC) of Nystatin against Candida albicans ATCC 10231, showing an MIC of 0.48 mg/L. essential oil inhibits virulence patterns of Candida spp. and potentiates the effects of fluconazole and nystatin in vitro.
Candida albicans ATCC 90029 0.33 mg/L (MIC) 24 hours Evaluation of the minimum inhibitory concentration (MIC) of Nystatin against Candida albicans ATCC 90029, showing an MIC of 0.33 mg/L. essential oil inhibits virulence patterns of Candida spp. and potentiates the effects of fluconazole and nystatin in vitro.
Pichia kudriavzevii 8-64 µg/ml 24-48 hours To evaluate the Minimum Inhibitory Concentration (MIC) and Minimum Fungicidal Concentration (MFC) of Nystatin against P. kudriavzevii. Results showed that 61.9% of isolates had dose-dependent sensitivity to Nystatin, while 28.57% were resistant. BMC Microbiol. 2024 Sep 10;24(1):333.
Candida albicans SC5314 0.25–1 µM 3 days Inhibition of filamentation in C. albicans, with enhanced efficacy when combined with 4-AQ derivatives NPJ Biofilms Microbiomes. 2024 Dec 13;10(1):146.
Candida dubliniensis 40/01 0.0156–16 µg/ml 48 hours To evaluate the effect of OligoG in combination with nystatin on the minimum inhibitory concentration (MIC) of Candida dubliniensis. Results showed a 32-fold reduction in MIC value when nystatin was used in combination with 6% OligoG. Front Cell Infect Microbiol. 2023 Jan 31;13:1122340.
Candida auris NCPF 8971 0.0156–16 µg/ml 48 hours To evaluate the effect of OligoG in combination with nystatin on the minimum inhibitory concentration (MIC) of Candida auris. Results showed a 2-fold reduction in MIC value when nystatin was used in combination with 6% OligoG. Front Cell Infect Microbiol. 2023 Jan 31;13:1122340.
Candida parapsilosis W23 0.0156–16 µg/ml 48 hours To evaluate the effect of OligoG in combination with nystatin on the minimum inhibitory concentration (MIC) of Candida parapsilosis. Results showed a 4-fold reduction in MIC value when nystatin was used in combination with 6% OligoG. Front Cell Infect Microbiol. 2023 Jan 31;13:1122340.
Candida albicans ATCC 90028 0.0156–16 µg/ml 48 hours To evaluate the effect of OligoG in combination with nystatin on the minimum inhibitory concentration (MIC) of Candida albicans. Results showed a 4-fold reduction in MIC value when nystatin was used in combination with 6% OligoG. Front Cell Infect Microbiol. 2023 Jan 31;13:1122340.
Candida albicans 3.9 to 500 µg/mL 48 hours To evaluate the inhibitory effect of Nystatin nanocomposites on the growth of Candida albicans. Results showed that nanocomposites significantly inhibited the growth of C. albicans at a concentration of 3.9 µg/mL. Molecules. 2023 Feb 15;28(4):1836.
C. albicans ATCC 26278 100 μg/mL Overnight To determine the minimum inhibitory concentration of Nystatin-PLP adduct, showing attenuated antifungal potency. Mol Pharm. 2011 Feb 7;8(1):297-301.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Zebrafish (Danio rerio) Disseminated candidiasis model 0.5–1 µM Assessed after 24-hour treatment Increased survival rate of infected embryos, with enhanced efficacy when combined with 4-AQ derivatives NPJ Biofilms Microbiomes. 2024 Dec 13;10(1):146.
ICR female mice Vulvovaginal candidiasis (VVC) model Vaginal perfusion 50.0 µL/dose Administered on days 1, 6, and 16, with therapeutic effects monitored Assess the therapeutic efficacy of ENNE against VVC, demonstrating significant reduction in vaginal fungal load and improved inflammatory response Int J Nanomedicine. 2020 Mar 25;15:2027-2044

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00659971 Oral Candidiasis Phase 2 Completed - United States, North Carolina ... More >> Rosedale Infectious Disease Huntersville, North Carolina, United States, 28078 Less <<
NCT01111942 Head and Neck Cancer Early Phase 1 Terminated(lack of enrollment) - United States, Illinois ... More >> Southern Illinois University School of Medicine Springfield, Illinois, United States, 62701 Less <<
NCT00814359 Head and Neck Cancer ... More >> Mucositis Less << Phase 3 Completed - Canada, Ontario ... More >> Juravinski Cancer Centre Hamilton, Ontario, Canada, L8V 5C2 Less <<
NCT01886001 Colonization Not Applicable Completed - United States, Virginia ... More >> Univeristy of Virginia Health System Charlottesville, Virginia, United States, 22908 Less <<
NCT01893060 Line Insertion Site ... More >> Central Line-associated Bloodstream Infection (CLABSI) Less << Not Applicable Unknown July 2014 United States, Virginia ... More >> University of Virginia HealthSystem Recruiting Charlottesville, Virginia, United States, 22932 Contact: David A Kaufman, MD    434-924-5428    dak4r@virginia.edu    Contact: Amy E. Blackman, MD    434-982-0263    as5v@virginia.edu Less <<
NCT00078559 - Completed - -
NCT03320460 Lichen Planus, Oral ... More >> Low-Level Light Therapy Less << Not Applicable Not yet recruiting December 2020 -
NCT02409147 Uterus Transplant Not Applicable Suspended(Lack of funding) January 2025 United States, Nebraska ... More >> University of Nebraska Medical Center Omaha, Nebraska, United States, 68198 Less <<
NCT03399331 Oral Mucositis ... More >> Leukemia Less << Phase 1 Recruiting July 1, 2021 Lebanon ... More >> American Univeristy of Beirut Medical Center Recruiting Beirut, Lebanon Contact: lina K Badr, PhD    01196132815041    lb24@aub.edu    Sub-Investigator: Rima Saad, MSN          Sub-Investigator: Rebecca El Asmar, MSN Less <<
NCT00078559 Kidney Transplantation ... More >> Kidney Disease Less << Phase 1 Phase 2 Completed - United States, Wisconsin ... More >> University of Wisconsin - Department of Medicine Madison, Wisconsin, United States, 53792-1735 Less <<
NCT00634166 Burns Phase 4 Terminated(FDA request as stud... More >>y could not serve as the confirmatory trial as required under Subpart H approval.) Less << - United States, Alabama ... More >> University of South Alabama Medical Center Mobile, Alabama, United States, 36617 United States, California Arrowhead Regional Medical Center Redlands, California, United States, 92373 United States, Florida Shands Burn Center - Univ. of Florida Gainesville, Florida, United States, 32610 United States, Illinois Loyola University Medical Center Maywood, Illinois, United States, 60153 The Plastic Surgery Institute - Southern Illinois Univ. School of Medicine Springfield, Illinois, United States, 62794-9653 United States, Kansas University of Kansas Medical Center Kansas City, Kansas, United States, 66160 United States, Maryland John's Hopkins Burn Center Baltimore, Maryland, United States, 21224 United States, Missouri University of Missouri Healthcare - Dept. of Surgery Columbia, Missouri, United States, 65212 United States, North Carolina Wake Forest University - Department of General Surgery Winston-Salem, North Carolina, United States, 27157 Less <<
NCT02142543 Minor Recurrent Aphthous Stoma... More >>titis Lesions Less << Early Phase 1 Completed - United States, Texas ... More >> Texas A&M Baylor College of Dentisry Dallas, Texas, United States, 75246 Less <<
NCT02208154 ICU-ecology (Multidrug Resista... More >>nt Bacteria) ICU-acquired Bacteraemia Less << Phase 3 Completed - Belgium ... More >> Universitair Ziekenhuis Antwerpen Edegem, Belgium, B-2650 Algemeen Ziekenhuis Sint Lucas Gent, Belgium, 9000 Universitair Ziekenhuis Gent Gent, Belgium, 9000 CHU Liege Liege, Belgium, 4000 Clinique Saint-Pierre Ottignies Ottignies, Belgium, 340 Italy Ospedale San Camillo Rome, Italy, 00152 Portugal Hospital Geral de Santo António (Centro Hospitalar do Porto, EPE) Porto, Portugal, 4099-001 Centro Hospitalar de Trás-os-Montes e Alto Douro, EPE Vila Real, Portugal, 5000 - 508 Slovenia University clinic of respiratory and allergic diseases Golnik, Slovenia, 4204 Spain Hospital Clinic of Barcelona Barcelona, Spain, 08036 l'Hospital de la Santa Creu i Sant Pau Barcelona, Spain, 08041 Hospital Universitario y Politécnico La Fé de Valencia Valencia, Spain, 46026 United Kingdom University Hospital of Wales Cardiff, United Kingdom, CF14 4XW Less <<
NCT00674999 Burn Phase 2 Phase 3 Withdrawn(Hurricane- terminate... More >>d study due to skin bank being destroyed) Less << - -
NCT01699412 Graft vs Host Disease ... More >> Oral Manifestations Less << Phase 3 Completed - Brazil ... More >> Hematology and Hemotherapy Center Campinas, São Paulo, Brazil, 13083-878 Clementino Fraga Filho University Hospital Rio de Janeiro, Brazil, 21941-913 Less <<
NCT00634166 - Terminated(FDA request as stud... More >>y could not serve as the confirmatory trial as required under Subpart H approval.) Less << - -
NCT00942526 Anastomotic Leakage Phase 2 Unknown December 2010 Taiwan ... More >> National Taiwan University Hospital Recruiting Taipei, Taiwan, 100 Contact: Pei-Ming Huang, MD    +886-2-23123456 ext 63509    e370089@gmail.com    Principal Investigator: Pei-Ming Huang, MD Less <<
NCT02515656 Vaginitis Phase 3 Completed - Czech Republic ... More >> TURKOVA Praha, Czech Republic France PERCEVAL Lyon, France, 69009 Serbia MARICIC Belgrade, Serbia Slovakia GATOVA Martin, Slovakia Less <<
NCT02389036 Critical Illness ... More >> Sepsis Septic Shock Ventilator Associated Pneumonia Less << Phase 3 Recruiting December 2020 Australia, New South Wales ... More >> The George Institute for Global Health Recruiting Sydney, New South Wales, Australia, 2000 Contact: John Myburgh, | MBBCh PhD    61 2 8052 4348    jmyburgh@georgeinstitute.org.au Less <<
NCT02444481 Vaginitis Phase 4 Completed - -
NCT01743690 Oral Lichen Planus ... More >> Candida Infection Less << Not Applicable Completed - Denmark ... More >> University of Copenhagen Copenhagen, Denmark, 2100 Less <<
NCT00845819 Oral Mucositis Phase 2 Completed - Korea, Republic of ... More >> Seoul National University Hospital Seoul, Korea, Republic of, 110-744 Less <<
NCT00629122 Kidney Failure, Chronic Phase 4 Completed - United States, New York ... More >> NewYork-Presbyterian Hospital New York, New York, United States, 10065 Less <<
NCT00629122 - Completed - -
NCT02662374 Oral Mucositis Phase 4 Unknown May 2016 -
NCT00002742 Chronic Myeloproliferative Dis... More >>orders Infection Leukemia Lymphoma Multiple Myeloma and Plasma Cell Neoplasm Myelodysplastic Syndromes Less << Phase 3 Completed - -
NCT01411748 Anticandidal Property of Sacch... More >>aromyces Boulardii on Very Low Birth Weight Infants Less << Phase 4 Unknown December 2011 Turkey ... More >> Zekai Tahir Burak Maternity Teaching Hospital, Division of Neonatology Recruiting Ankara, Turkey, 06230 Contact: Gamze Demirel, MD    +905324540156    kgamze@hotmail.com    Principal Investigator: Gamze Demirel, MD Less <<
NCT00250133 - Terminated(Unable to obtain fu... More >>nding to complete study never started study) Less << - United States, Pennsylvania ... More >> University of Pittsburgh Medical Center Pittsburgh, Pennsylvania, United States, 15213 Less <<
NCT02166450 Denture Stomatitis UNKNOWN - Zbigniew ?ak Voivodeship Denta... More >>l Clinic, Krakow, 31-135, Poland|Jagiellonian University Dental Clinic, Krakow, 31-155, Poland Less <<
NCT03237533 Oral Lichen Planus Early Phase 1 Recruiting December 31, 2017 Pakistan ... More >> The university of Faisalabad Recruiting Faisalābād, Punjab, Pakistan, 38000 Contact: Sadaf Rashid, BDS    +923237791689    durr_e_sadaf@hotmail.com    Contact: Arsalan Wahid, M. Phil    +923216685228    dr.arsalanmalik@gmail.com Less <<
NCT00128323 Candidiasis, Oral Phase 3 Completed - Malawi ... More >> Queen Elizabeth Central Hospital, Paediatric Dept, Box 360 Blantyre, Malawi, 3 Less <<
NCT01798537 Bacteremia Associated With Int... More >>ravascular Line Ventilator Associated Pneumonia Bacteremia Less << Phase 2 Phase 3 Unknown July 2015 Israel ... More >> Rambam Health Care Campus Not yet recruiting Haifa, Israel, 31096 Contact: Yaron P Bar-Lavie, M.D.    ++972-50-206-2027    y_barlavie@rambam.health.gov.il    Contact: Mical Paul, Prof.    ++972-50-206-2140    m_paul@rambam.health.gov.il    Principal Investigator: Yaron P Bar-Lavie, M.D.          Principal Investigator: Mical Paul, Prof. Less <<
NCT01867164 - Completed - -
NCT00002112 Candidiasis, Oral ... More >> HIV Infections Less << Not Applicable Completed - United States, California ... More >> California Med Research Group Fresno, California, United States, 93726 UCSF Hosp San Francisco, California, United States, 94143 United States, Maryland Johns Hopkins School of Medicine Baltimore, Maryland, United States, 21205 United States, Pennsylvania Med College of Pennsylvania Philadelphia, Pennsylvania, United States, 19129 United States, Virginia Hampton Roads Med Specialists Hampton, Virginia, United States, 23666 Less <<
NCT01867164 Vaginitis Inf... More >>ectious Vaginosis Less << Phase 3 Completed - Mexico ... More >> DF, Mexico Mexico D.F., Mexico Less <<
NCT01718912 Periodontal Disease Not Applicable Completed - Canada, Ontario ... More >> Toronto Rehabilitation Institute, Dental Department Toronto, Ontario, Canada, M5G 2A2 Less <<
NCT00001812 Candidiasis, Oral|Gastrointest... More >>inal Diseases|Stomatitis Less << PHASE3 COMPLETED 2000-08-01 National Cancer Institute (NCI... More >>), Bethesda, Maryland, 20892, United States Less <<
NCT01531192 Very Low Birth Weight Infants Phase 4 Completed - Turkey ... More >> Zekai Tahir Burak Maternity Teaching Hospital, Division of Neonatology Ankara, Turkey, 06110 Less <<
NCT00002293 Candidiasis, Oral|HIV Infectio... More >>ns Less << COMPLETED - Birmingham Veterans Administra... More >>tion Med Ctr / Univ of Alabama, Birmingham, Alabama, 35233, United States|Bristol - Myers Squibb Co, Princeton, New Jersey, 085434000, United States Less <<
NCT00002057 Candidiasis, Oral|HIV Infectio... More >>ns Less << COMPLETED - Birmingham Veterans Administra... More >>tion Med Ctr / Univ of Alabama, Birmingham, Alabama, 35233, United States|Bristol - Myers Squibb Co, Princeton, New Jersey, 085434000, United States Less <<
NCT00001998 HIV Infections COMPLETED - Twelve Oaks Hosp, Houston, Tex... More >>as, 77027, United States Less <<
NCT00002313 HIV Infections Phase 1 Completed - United States, Texas ... More >> Twelve Oaks Hosp Houston, Texas, United States, 77027 Less <<
NCT01198223 Denture Stomatitis Phase 2 Completed - Iran, Islamic Republic of ... More >> QUMS Qazvin, Iran, Islamic Republic of Less <<
NCT02642900 Photochemotherapy Reaction Phase 4 Completed - Brazil ... More >> Faculdade de Odontologia da Universidade de São Paulo São Paulo, Brazil, 05508-000 Less <<
NCT01427738 - Completed - -
NCT02186145 Bacterial Vaginosis ... More >> Fungal Vaginal Infections Less << Phase 3 Unknown January 2017 Brazil ... More >> Faculty of Medicine of ABC (FMABC) Not yet recruiting Santo André, SP, Brazil, 09190-615 Contact: Marcus Vinícius Seroqui, Site Clinical Trials Manager    +55 11 2829-5148    mv_seroqui@yahoo.com.br    Principal Investigator: Emerson Oliveira, MD Less <<
NCT03390374 Fungal Infections Systemic Phase 4 Completed - -
NCT00002097 HIV Infections PHASE1 COMPLETED - Twelve Oaks Hosp, Houston, Tex... More >>as, 77027, United States Less <<
NCT01495039 Fungal Prophylaxis|Candida Inf... More >>ection|Critical Illness|Surgery Less << PHASE4 COMPLETED 2025-02-10 Intensive care Unit, Policlini... More >>co Hospital Bari, Bari, 70100, Italy Less <<
NCT01427738 HIV-1 Infection Phase 3 Completed - Botswana ... More >> Gaborone Prevention/Treatment Trials CRS (12701) Gaborone, Botswana Molepolole Prevention/Treatment Trials CRS (12702) Molepolole, Botswana India BJ Medical College CRS (31441) Pune, Maharashtra, India, 411001 National AIDS Research Institute Pune CRS (11601) Pune, Maharashtra, India, 411026 Kenya AMPATH at Moi Univ. Teaching Hosp. Eldoret CRS (12601) Eldoret, Kenya, 30100 Walter Reed Project - Kenya Med. Research Institute Kericho CRS (12501) Kericho, Kenya, 20200 Malawi College of Med. JHU CRS (30301) Blantyre, Malawi South Africa Durban Adult HIV CRS (11201) Durban, South Africa, 4013 SF Uganda Joint Clinical Research Centre (JCRC) (12401) Kampala, Uganda Zimbabwe UZ-Parirenyatwa CRS (30313) Harare, Zimbabwe Less <<
NCT04550546 Dental Caries PHASE1 COMPLETED 2022-02-28 Eastman Dental Institute, Roch... More >>ester, New York, 14642, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.08mL

0.22mL

0.11mL

5.40mL

1.08mL

0.54mL

10.80mL

2.16mL

1.08mL

References

 

Historical Records

Categories